
Legend Capital invests in Yixintang Drugstore and eBen
Beijing-headquartered VC firm Legend Capital reportedly aims to invest RMB150million ($22 million) in Yixintang Drugstore, the seventh-largest drugstore chain operator in China, to support its expansion in the region.
Yixintang currently operates its outlets in regions including Yunnan, Guangxi, Sichuan and Guizhou provinces, and reportedly generated revenue of RMB2 billion ($295 million) in 2009.
Separately, Legend Capital will make its second investment of RMB56 million ($8.3 million) in Beijing-based tablet PC manufacturer eBen with Tsinghua Science Park Capital. The event follows its first capital injection made in August 2009. Its investment partner in the recent deal is the VC firm founded by China's Tsinghua University, which has a focus on science and technology investments. With the capital, eBen plans to increase its number of demonstration storefronts and add staff. It recently announced the development of a tablet computer features a seven-inch TFT display, 3G and Wi-Fi connectivity.
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.